The War on Drugs has cost over $1 trillion in federal spending since 1971 while drug use rates remain unchanged. 806,000 Americans have died from opioid overdoses. Black Americans are arrested at 3.73× the rate of white Americans despite equal drug use. Americans are 45× more likely to die of overdose than the Portuguese, who decriminalized all drugs in 2001. The war failed. The evidence points elsewhere. We follow the evidence.
Drug addiction is a public health crisis, not a criminal justice problem. The distinction is not semantic — it determines whether we build treatment centers or prisons, whether we employ doctors or prison guards, whether we measure success in lives saved or arrests made. Fifty years of the War on Drugs have answered the question of whether punishment works. It does not. The evidence from Portugal, Switzerland, Germany, and 24 US states that legalized cannabis answers the question of what does.
Twelve pillars — replacing punishment with evidence: Federal cannabis legalization with regulated market. Automatic expungement of all cannabis convictions. Decriminalization of personal possession using the Portuguese model. Massive treatment expansion with universal MAT access. Harm reduction infrastructure — supervised consumption sites, naloxone, fentanyl test strips. Criminal accountability for pharmaceutical executives. FDA-regulated psychedelic therapy. Science-based drug scheduling reform. Elimination of all mandatory minimums. Community reinvestment from cannabis tax revenue. Diplomatic fentanyl supply-chain disruption. Ban on private prison profiteering.
Over $1 trillion in federal spending since 1971, with states spending roughly double. Drug use rates: unchanged over five decades. Cannabis seizures increased 465% while prices fell 86% and potency rose 161%. Drug arrests surged from 300,000 to 1.16 million per year. More enforcement produced cheaper, stronger, more available drugs. The DEA's budget grew 228% in real terms while achieving nothing measurable. This is not a policy that failed gradually — it is a policy that could not have worked because its architects admitted it was never designed to work.
Nixon's domestic policy chief John Ehrlichman admitted in 1994: "We knew we couldn't make it illegal to be either against the war or Black, but by getting the public to associate the hippies with marijuana and Blacks with heroin, and then criminalizing both heavily, we could disrupt those communities... Did we know we were lying about the drugs? Of course we did." The War on Drugs was born as a political weapon. Its results prove it was deployed as one.
Black and white Americans use drugs at roughly equal rates. Black Americans are arrested at 3.73× the rate. Since 2000, police made over 16 million marijuana arrests — the vast majority for simple possession. The crack/powder disparity encoded racism into sentencing law: 5 grams of crack triggered the same mandatory minimum as 500 grams of powder cocaine. Crack concentrated in Black communities; powder in white ones. 4 million Americans have been denied voting rights due to felony drug convictions. One in 22 Black voting-age Americans is currently disenfranchised.
806,000 Americans dead from opioid overdoses since 1999. The annual economic cost: $2.7–$4 trillion — approaching 10% of GDP. The Sackler family engineered this crisis through systematic deception, falsely claiming OxyContin lasted 12 hours and inventing the concept of "pseudoaddiction" to override physician concern. They withdrew $12.2 billion from Purdue Pharma into offshore trusts as deaths accelerated. No Sackler has served a day in prison.
The Anti-Drug Abuse Act of 1986 created the 100:1 crack/powder cocaine disparity — 5 grams of crack triggered the same mandatory minimum sentence as 500 grams of powder cocaine. The pharmacological difference between crack and powder cocaine is negligible. The demographic difference in who used each was not. From 1980 to 1997, nonviolent drug incarcerations rose from 50,000 to 400,000. The US Sentencing Commission concluded the disparity had "created a racial imbalance in federal prisons" — and recommended elimination. Congress reduced it to 18:1 in 2010. This platform eliminates it entirely.
Purdue Pharma falsely claimed OxyContin lasted 12 hours when their own research showed it wore off in four — creating pain cycles that drove repeat dosing and dependency. They promoted "pseudoaddiction" — a fabricated concept — to explain away physician concerns as undertreating pain. They marketed reformulated OxyContin as "abuse deterrent" without evidence. Purdue pleaded guilty in 2007 and paid $630 million — then continued the same behavior until 2019. Total opioid settlements across all manufacturers and distributors likely exceed $50 billion. The annual cost of the crisis they created: $600 billion to $4 trillion.
The Lancet's landmark 2010 harm assessment — the most rigorous evidence-based drug harm analysis published — reveals the incoherence of current US scheduling:
| Substance | Harm Score (Lancet) | US Schedule | Status |
|---|---|---|---|
| Alcohol | 72 — most harmful | Unscheduled | Freely sold, taxed, advertised |
| Heroin | 55 | Schedule I | No accepted medical use recognized |
| Crack cocaine | 54 | Schedule II | 18:1 disparity vs. powder |
| Methamphetamine | 33 | Schedule II | Prescribed as Desoxyn |
| Tobacco | 26 | Unscheduled | Freely sold, marketed |
| Cannabis | 20 | Schedule I | Classified alongside heroin |
| MDMA | 9 | Schedule I | Blocks therapeutic research |
| Psilocybin | 5 — least harmful | Schedule I | 67% depression remission at 5 years |
The two most harmful substances by evidence are unscheduled and commercially available. The three least harmful are Schedule I — blocking both access and research. The scheduling system does not reflect harm. It reflects politics and historical accident.
Sources: The Lancet — thelancet.com · Brennan Center — brennancenter.org
In 2001, Portugal decriminalized personal possession of all drugs. Trafficking remained criminal. Personal use became an administrative offense handled by health-focused dissuasion commissions staffed by social workers, lawyers, and medical professionals. The results after two decades are unambiguous:
Drug use prevalence in Portugal is now below the EU average. Use did not increase after decriminalization. The policy change was paired with massive investment in treatment and social services — Portugal demonstrates that decriminalization without health infrastructure is insufficient, and that decriminalization with it transforms outcomes.
Switzerland pioneered heroin-assisted treatment (HAT) in 1994 — approved by 70% of voters in a national referendum. The evidence after three decades: overdose deaths decreased 64% by 2016; HIV infections down 65%; new heroin users down 80%; opioid-related crime dropped from 20,000 incidents per year to 5,000. Crime reductions alone exceeded the total cost of treatment. HAT retention at 12 months: 93% — far exceeding any conventional treatment. Switzerland's model has been adopted by Denmark, Germany, the Netherlands, the UK, and Canada.
| Metric | Result | Source |
|---|---|---|
| Total cannabis tax revenue since 2014 | $24.7 billion across legal states | Marijuana Policy Project |
| Youth cannabis use after legalization | Declined in 19 of 21 states | Multiple state surveys |
| Colorado youth use rate | 19.7% → 12.8% — lowest in a decade | Colorado Sun / state data |
| Dispensary ID compliance (minors) | 99% denied — vs. illicit market: 0% | State compliance audits |
| Cannabis-related arrests | Fell dramatically in all legal states | NORML / FBI UCR |
| Honest negative: traffic crashes | Increased ~6.5% in early-legalization states | IIHS research |
| Honest negative: illicit market | Persists where tax rates are too high (California) | RAND / California DOJ |
Sources: Drug Policy Alliance — drugpolicy.org · Stanford Social Innovation Review — ssir.org · MPP — mpp.org
Twelve pillars moving from punishment to evidence across every dimension of drug policy: access, enforcement, treatment, prevention, justice, and accountability. Each pillar is independently justified by evidence. Together they represent a complete transition from the criminal justice model to the public health model.
Cannabis is less harmful than alcohol, tobacco, cocaine, or methamphetamine by every evidence-based metric (Lancet harm score: cannabis 20, alcohol 72). 24 states have legalized with $24.7 billion in tax revenue generated since 2014. Youth use declined in 19 of 21 states. Dispensaries denied minors in 99% of compliance checks. The case for continued federal criminalization is incoherent.
16+ million marijuana arrests have been made since 2000. Illinois: 780,000+ charges eligible for expungement. New Jersey: 362,000. New York: 310,000+. You cannot legalize a substance and leave millions of people — disproportionately Black and brown Americans — with criminal records for what is now legal conduct.
Portugal decriminalized personal possession of all drugs in 2001. Over 20+ years: overdose deaths down 80%+, HIV down 95%, incarceration down 60%+, drug use did not increase and is now below the EU average. Americans are 45× more likely to die of overdose. The policy evidence is definitive.
Treatment returns $4–12 per dollar invested through reduced crime, emergency care costs, and restored productivity — versus $33–70K/year to incarcerate the same person. Less than one-third of overdose survivors currently receive any medication-assisted treatment (MAT). Release from incarceration without MAT creates a 13× higher overdose death risk.
Zero deaths have ever been recorded at any supervised consumption site worldwide. NYC OnPoint: 48,533 visits in its first year, 636 overdose reversals, zero deaths, 39,000 instances of public drug use prevented. Naloxone returns $2,742 per dollar invested. Needle exchanges reduce HIV transmission 40–60% and make participants 5× more likely to enter treatment.
The Sacklers withdrew $12.2 billion from Purdue Pharma into offshore trusts as opioid deaths accelerated. Purdue pleaded guilty twice — in 2007 and 2022 — and continued the same behavior between pleas. Total opioid settlements may exceed $50 billion. The annual cost of the crisis they engineered: $600 billion to $4 trillion. No Sackler has served a day in prison.
Psilocybin produces 67% remission in major depression at 5-year follow-up (Johns Hopkins) with single-dose improvement within 8 days (JAMA). MDMA-assisted therapy produces 67–71% of PTSD patients no longer meeting diagnostic criteria. Lethal dose is approximately 1,000× recreational dose. 34 studies show no long-term adverse effects. 50% of military PTSD patients continue meeting full diagnostic criteria after first-line therapy. Oregon has served 8,000 people. Australia now prescribes both psilocybin and MDMA.
The current Controlled Substances Act classifies cannabis (harm score 20) alongside heroin (55) as Schedule I, while alcohol (72) remains entirely unscheduled. MDMA (9) and psilocybin (5) are Schedule I — blocking both therapeutic access and research — while methamphetamine (33) is Schedule II and available by prescription as Desoxyn. The scheduling system is not based on harm evidence.
35 years of evidence shows long mandatory sentences are not effective at reducing drug use or drug crime. Mandatory minimums remove judicial discretion, producing unjust outcomes while doing nothing to deter drug-related behavior. 91% of FIRST STEP Act beneficiaries — the law that reduced some mandatory minimums — were African American, confirming their racially disproportionate application.
Communities that absorbed the most harm from the War on Drugs — through arrests, incarceration, family separation, disinvestment, and destabilization — must be the primary beneficiaries of the transition to evidence-based policy. Illinois's R3 program (Restore, Reinvest, Renew) provides the model: $244 million in grants directed to the highest-arrest ZIP codes, funded by 25% of cannabis tax revenue.
Fentanyl is a supply-chain crisis requiring diplomatic and intelligence responses, not a border wall. The supply chain runs: Chinese precursor chemicals → Mexican cartel synthesis labs → US ports of entry. The 2024 overdose decline (−26.2%) — the largest ever recorded — was driven by harm reduction expansion, not enforcement escalation. Supply-side crackdowns produced fentanyl in the first place by making heroin scarce and pushing the market toward synthetics.
CoreCivic stated in SEC filings that its business model is threatened by "relaxation of enforcement efforts" and "decriminalization of certain offenses." GEO Group and CoreCivic earned over $4 billion combined in FY2017. Many private prison contracts include minimum occupancy clauses requiring 80–90% capacity — financial incentives for incarceration that no public institution has. No corporation should profit from human incarceration.
The War on Drugs costs $44.5 billion per year in federal spending alone — with states spending roughly double. Cannabis legalization generates $4.4 billion annually in federal tax revenue, growing. Opioid settlements exceed $50 billion in directed abatement funds. Treatment at $5K per person returns $4–12 per dollar. The question is not whether evidence-based policy costs money — it is whether we can afford another trillion on what demonstrably does not work.
| Policy | Fiscal Position | Mechanism / Savings |
|---|---|---|
| Cannabis legalization | Revenue-generating | $24.7B in tax revenue since 2014; $4.4B in 2024 alone and growing |
| Cannabis expungement | Modest cost | Administrative; reduces long-term corrections and court costs |
| Decriminalize possession | Net savings | Eliminates 1.16M annual arrests; redirects enforcement resources to treatment |
| Treatment expansion | $5K/person/year | Returns $4–12 per dollar; replaces $33–70K incarceration costs |
| Harm reduction | Cost-effective | Naloxone: $2,742 returned per dollar; supervised consumption: 5.12:1 benefit-cost |
| Pharma accountability | Revenue-generating | $50B+ opioid settlements directed to abatement programs |
| Psychedelic therapy | Research funding | FDA pathway; Oregon model self-funding through licensing fees |
| End mandatory minimums | Net savings | Reduces $33–70K/year per incarcerated person; retroactive resentencing |
| Community reinvestment | Cannabis tax funded | 25% of cannabis revenue — Illinois R3 model; offset by reduced emergency costs |
| Ban private prisons | Net savings | Eliminates profit incentive for incarceration; reinvests in public rehabilitation |
Source: Center for American Progress — americanprogress.org
Sources: Transform — transformdrugs.org · IDPC/NEJM — idpc.net · Drug Policy Alliance — drugpolicy.org
| Statistic | Figure | Source |
|---|---|---|
| Federal War on Drugs spending since 1971 | $1+ trillion (states: roughly double) | Harm Reduction International |
| Drug use rates after 50 years of the War | Unchanged | Leadership Conference |
| Black vs. white marijuana arrest rate | 3.73× despite equal use | ACLU |
| Marijuana arrests since 2000 | 16 million+ | NORML |
| Opioid overdose deaths since 1999 | 806,000 | CDC |
| 2024 overdose decline | −26.2% — largest ever (driven by harm reduction) | CDC |
| Opioid crisis annual economic cost | $2.7–$4 trillion | White House CEA |
| Sackler family withdrawals from Purdue | $12.2 billion into offshore trusts | NPR |
| US vs. Portugal overdose death rate | Americans 45× more likely to die | NPR / Commonwealth Fund |
| Portugal: overdose deaths since decrim | −80%+ (1999–2015) | Drug Policy Alliance |
| Portugal: HIV cases (injecting users) | −95% (2000–2013) | Drug Policy Alliance |
| Switzerland: new heroin users since HAT | −80% | Stanford Social Innovation Review |
| Cannabis tax revenue since 2014 | $24.7 billion across legal states | MPP |
| Youth cannabis use after legalization | Declined in 19 of 21 states | Multiple state surveys |
| Psilocybin: major depression remission | 67% at 5 years (Johns Hopkins) | Johns Hopkins / JAMA |
| MDMA: PTSD no longer meeting criteria | 67–71% of patients | MAPS clinical trials |
| Treatment cost vs. incarceration | $5K/yr vs. $33–70K/yr | Center for American Progress |
| Treatment return on investment | $4–12 per dollar invested | NIH / NIDA |
| Naloxone return on investment | $2,742 per dollar | CDC health economics |
| Supervised consumption sites: deaths | Zero — worldwide, ever | International peer-reviewed literature |
Drug policy sits at the intersection of healthcare, criminal justice, racial justice, veterans' affairs, and police reform. Each of these issues is shaped by drug enforcement decisions — and each must change together for the transition from punishment to public health to succeed.
"The War on Drugs was born as a political weapon, not a public health policy. Its architect admitted it. Its results prove it. This is the single clearest case in this entire platform where the evidence points one direction and current policy points the other. We follow the evidence."— The Common Good Party